Staar Surgical Swiss Manufacturing Facility Ready For AquaFlow Production
This article was originally published in The Gray Sheet
Staar Surgical expects to receive FDA approval of its AquaFlow extra-ocular collagen-based glaucoma drainage device in the next two-to-five weeks.
You may also be interested in...
Staar Surgical should collect expanded two-year follow-up data for patients treated with the AquaFlow collagen glaucoma drainage device as a condition of FDA approval, the agency's Ophthalmic Devices Advisory Panel recommended Nov. 8 in Gaithersburg, Maryland.
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.